利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.067 秒)

    Glycine transporter-1 inhibitors
    5.
    发明授权
    Glycine transporter-1 inhibitors 有权
    甘氨酸转运蛋白-1抑制剂

    公开(公告)号：US08258306B2

    公开(公告)日：2012-09-04

    申请号：US12746755

    申请日：2008-12-11

    申请人： Stephen A. Hitchcock ,  Wenyuan Qian ,  Albert Amegadzie

    发明人： Stephen A. Hitchcock ,  Wenyuan Qian ,  Albert Amegadzie

    IPC分类号： C07D211/34

    CPC分类号： C07D211/50 ,  C07D241/06

    摘要： The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

    摘要翻译： 本发明提供了作为甘氨酸转运蛋白1（以下称为GlyT-1）抑制剂的化合物，因此可用于治疗通过抑制GlyT1可治疗的疾病，例如与精神分裂症，ADHD（注意缺陷多动障碍）相关的认知障碍， MCI（轻度认知障碍）等。 还提供含有这些化合物的药物组合物和制备这些化合物的方法。

    Glycine Transporter-1 Inhibitors
    6.
    发明申请
    Glycine Transporter-1 Inhibitors 有权
    甘氨酸转运蛋白-1抑制剂

    公开(公告)号：US20100298341A1

    公开(公告)日：2010-11-25

    申请号：US12746755

    申请日：2008-12-11

    申请人： Stephen A. Hitchcock ,  Wenyuan Qian ,  Albert Amegadzie

    发明人： Stephen A. Hitchcock ,  Wenyuan Qian ,  Albert Amegadzie

    IPC分类号： A61K31/495 ,  C07D241/04 ,  C07D211/34 ,  C07D207/08 ,  A61K31/445 ,  A61K31/40 ,  A61P25/18

    CPC分类号： C07D211/50 ,  C07D241/06

    摘要： The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

    摘要翻译： 本发明提供了作为甘氨酸转运蛋白1（以下称为GlyT-1）抑制剂的化合物，因此可用于治疗通过抑制GlyT1可治疗的疾病，例如与精神分裂症，ADHD（注意缺陷多动障碍）相关的认知障碍， MCI（轻度认知障碍）等。 还提供含有这些化合物的药物组合物和制备这些化合物的方法。

    Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use
    10.
    发明申请
    Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use 有权
    氨基杂芳基化合物作为β-分泌酶调节剂和使用方法

    公开(公告)号：US20130018064A1

    公开(公告)日：2013-01-17

    申请号：US13511360

    申请日：2010-11-19

    申请人： Nick A. Paras ,  Yuan Cheng ,  Timothy Powers ,  James Brown ,  Stephen A. Hitchcock ,  Ted Judd ,  Patricia Lopez ,  Qiufen Xue ,  Bryant Yang

    发明人： Nick A. Paras ,  Yuan Cheng ,  Timothy Powers ,  James Brown ,  Stephen A. Hitchcock ,  Ted Judd ,  Patricia Lopez ,  Qiufen Xue ,  Bryant Yang

    IPC分类号： A61K31/506 ,  A61P25/28 ,  A61K31/4709 ,  C07D401/08 ,  C07D401/06

    CPC分类号： C07D401/06 ,  C07D401/12 ,  C07D401/14

    摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I, wherein ring A, B1, B2, B3, L, R1, R4, ring Z, m and p of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

    摘要翻译： 本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默病（AD））和相关病症的新一类化合物。 在一个实施方案中，化合物具有通式I，其中式I的环A，B 1，B 2，B 3，L，R 1，R 4，环Z，m和p如本文所定义。 本发明还包括在药物组合物中用于治疗，预防或治疗与β-分泌酶蛋白活性相关的病症和病症的用途。 这些疾病包括例如阿尔茨海默氏病（AD），认知缺陷，认知障碍，精神分裂症和与脑上形成和/或沉积斑块相关和/或引起的其他中枢神经系统病症。 本发明还包括式I的其它实施方案，可用于制备式I化合物的中间体和方法。